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Abstract
Among Caliciviridae, the norovirus genus encompasses enteric viruses that infect humans as well as several animal species,
causing gastroenteritis. Porcine strains are classified together with human strains within genogroup II, whilst bovine
norovirus strains represent genogroup III. Various GI and GII human strains bind to carbohydrates of the histo-blood group
family which may be shared among mammalian species. Genetic relatedness of human and animal strains as well as the
presence of potentially shared ligands raises the possibility of norovirus cross-species transmission. In the present study, we
identified a carbohydrate ligand for the prototype bovine norovirus strain Bo/Newbury2/76/UK (NB2). Attachment of virus-
like particles (VLPs) of the NB2 strain to bovine gut tissue sections showed a complete match with the staining by reagents
recognizing the Gala1,3 motif. Alpha-galactosidase treatment confirmed involvement of a terminal alpha-linked galactose.
Specific binding of VLPs to the aGal epitope (Gala3Galb4GlcNAcb-R) was observed. The binding of Gala3GalaOMe to rNB2
VLPs was characterized at atomic resolution employing saturation transfer difference (STD) NMR experiments. Transfection
of human cells with an a1,3galactosyltransferase cDNA allowed binding of NB2 VLPs, whilst inversely, attachment to porcine
vascular endothelial cells was lost when the cells originated from an a1,3galactosyltransferase KO animal. The aGal epitope
is expressed in all mammalian species with the exception of the Hominidaea family due to the inactivation of the
a1,3galactosyltransferase gene (GGTA1). Accordingly, the NB2 carbohydrate ligand is absent from human tissues. Although
expressed on porcine vascular endothelial cells, we observed that unlike in cows, it is not present on gut epithelial cells,
suggesting that neither man nor pig could be infected by the NB2 bovine strain.
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Introduction
Caliciviruses are small non enveloped viruses approximately
27–35 nm in diameter with a positive-sense single-stranded RNA
genome of 7.4 to 8.3 kb in size. Based on genomic organization
and genetic analysis, the Caliciviridae family is divided into five
genera, norovirus, sapovirus, vesivirus, lagovirus and becovirus (or
nabovirus), and a sixth genus ‘‘recovirus’’ has been recently
proposed [1]. Animal caliciviruses are suspected and confirmed
causes of a wide spectrum of diseases including gastroenteritis
(pigs, calves, cats, dogs and chickens), vesicular lesions and
reproductive failure (pigs and sea lions), respiratory infections
(cats and cattle) and a fatal hemorrhagic disease (rabbits and hares)
[2]. Human and animal caliciviruses associated with gastroenteritis
belong to the norovirus and sapovirus genera. The genus
norovirus (NoV) has been divided into five genogroups,
genogroups I to V [3]. More recently, a classification including
two additional genogroups (VI and VII) has been suggested [4].
Human strains are classified into genogroups I, II, IV, VI and VII.
Analysis of the complete ORF2 sequences, encoding the capsid
protein, of genogroups I and II demonstrates high diversity and at
present, 8 clusters have been defined within genogroup I (GI-1 to
GI-8) and 19 within genogroup II (GII-1 to GII-19). Porcine NoV
have been classified into GII-11 and recently into two novel
genotypes (GII-18 and GII-19) [5]. NoV are also detected in
calves. The first bovine NoV strain, Bo/Newbury2/1976/UK,
was isolated from calves with diarrhea in the United Kingdom [6].
Later, another distinct genotype of bovine NoV, Bo/jena/78/
GER was identified in Germany [7]. They belong to genogroup
III [8,9,10], in which the Jena virus and the Newbury2 (NB2) are
respectively the prototype of genotypes GIII-1 and GIII-2. Two
other enteric bovine caliciviruses have been described, the
Newburry agent 1 in the UK [11] and Nebraska strain in the
USA [12]. Thus, a fifth genus named becovirus (or nabovirus)
includes these two bovine viruses since they present significant
differences with the other genera of the Caliciviridae family [13].
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blood group antigens (HBGAs), with different strains showing
distinct specificities [14,15]. HBGAs are complex glycans present
on many cell types including red blood cells and vascular
endothelial cells, as well as on the epithelia of the gastrointestinal,
uro-genital and respiratory tracts. They can also be present in a
soluble form in biologic fluids such as saliva and milk. HBGAs are
synthesized from a series of precursor structures by stepwise
addition of monosaccharide units via a set of glycosyltransferases.
According to the CAZY classification (http://www.cazy.org/),
three glycosyltransferases families are involved in their biosynthe-
sis. The GT11, GT10 and GT6 families which encode a1, 3/
4fucosyltransferases, a1,2fucosyltransferases and enzymes related
to the A and B enzymes of the ABO system, respectively. Some of
the corresponding genes are polymorphic whilst others are
expressed in a species-specific manner. In humans, the pleiotropic
interaction of alleles at three loci, FUT3, FUT2 and ABO
determines the Lewis, Secretor, and ABO phenotypes, respectively
[16]. The corresponding antigens are involved in HuNoV
recognition of human digestive tissue and are required for
infection [14,15]. The GT6 gene family (ABO family) comprises
three other members which encode a1,3galactosyl or N-acetylga-
lactosaminyltransferases. An a1,3galactosyltransferase acts on the
type 2 precursor disaccharide (Galb4GlcNAc) to give the aGal
epitope, also called Galili antigen (Gala3Galb4GlcNAc), which is
expressed in all mammalian species except hominids since in
humans, gorilla and chimpanzee the GGTA1 (glycoprotein, alpha-
galactosyltransferase 1) gene has been inactivated by several
mutations and is therefore a pseudogene [17]. Another gene of the
same family encodes a distinct a1,3galactosyltransferase which acts
on the glycosphingolipid lactosylceramide to generate the
isoglobotrihexosylceramide (iGb3: Gala3Galb4Glcb-Cer). The
corresponding iGb3 synthase gene does not appear to be
functional in humans, although this is actively debated [18,19].
Finally, the last enzyme of the GT6 family known at present is an
a1,3N-acetylgalactosaminyltransferase which acts on the glyco-
sphingolipid called globoside (Gb4) or P blood group antigen to
generate the Forsmann antigen (GalNAca3GalNAcb3Gala4-
Galb4Glc-Cer). This enzyme, the Forsmann synthase, is not
active in humans [20]. Recently, our group described other genes
of the GT6 family (GT6m5 to GT6m8). However, they are not
present in all vertebrate or mammalian genomes and the enzyme
activity of the corresponding proteins have not been characterized
as yet [21].
The genetic and antigenic relatedness of human and animal
noroviruses suggests the possibility for inter-species transmission as
illustrated by the recent detection of sequences close to GII-4
HuNoV in swine and cattle in Canada [22,23]. Although animal
NoVs have not yet been isolated from human, human infection
with NoV related to genogroup III bovine NoV has been
suggested by the presence of serum antibodies against bovine
GIII-2 among veterinarians in the Netherlands [23]. Moreover the
use of phylogenetically conserved cellular receptors appears as
another risk factor for cross-species transmission. Attachment of
the virus to a host ligand constitutes a first step of the viral
infection process, and it has been observed that when the receptor
is conserved between several species, these are more likely to be
infected by viruses that use the shared receptor [24]. HBGAs can
be conserved across high phylogenetic distances as shared epitopes
have been found between bacteria, invertebrates, plants and
mammal [25]. ABH-related structures have been characterized in
the gut of all mammalian species tested so far [26]. The use of such
molecules as primary ligands by HuNoV strains as well as by
RHDV [27], a rabbit calicivirus of the lagovirus genus, prompted
us to look for the ability of a bovine NoV to recognize HBGAs
potentially present on bovine, as well as on porcine and human
digestive epithelial cells. Such a shared ligand could help these
viruses to propagate between the three species which live in close
contact and at high densities in areas of intensive breeding.
Results
Recombinant NB2 VLPs bind to bovine digestive tract
cells through a carbohydrate ligand distinct from A, B, H
or Lewis histo-blood group antigens
We previously demonstrated the binding of VLPs of calici-
viruses to carbohydrate epitopes using immunohistochemistry as a
starting method [27,28]. We now used the same method in order
to determine if the bovine NB2 strain of norovirus could similarly
bind to a carbohydrate ligand expressed in the gut. Tissue sections
prepared from the entire bovine gut were thus incubated with
rNB2 VLPs and their binding was detected using antibodies.
Specific staining, only visible in the presence of VLPs, was readily
observed as shown on Fig. 1. In the duodenum, rNB2 VLPs
attached to the epithelial cells of the crypts of Lieberku ¨hn located
at the surface of the mucosa (Fig. 1A), but not to the epithelial cells
of the Bru ¨nner’s glands which are located deeper in the mucosa
(Fig. 1B). Unlike what was previously observed for other
caliciviruses, binding of the VLPs was not restricted to epithelial
cells. It was also observed on vascular endothelial cells and
erythrocytes. These are clearly visible surrounding Bru ¨nner’s
glands (Fig. 1B) or in the serosa layer (Fig. 1C). In addition, other
cell types such as smooth muscle cells were labelled, albeit less
strongly. In order to determine if the binding involved recognition
of carbohydrate epitopes, tissue sections were pretreated with
sodium periodate prior to incubation with the VLPs since
periodate oxidation cleaves C-C bonds with vicinal hydroxyl
groups as found on sugars. Sialic acid residues are more sensitive
to mild oxidation than other sugars. Since many viruses are known
to use sialic acids as ligands [29], bovine duodenal tissue sections
were first treated with 1 mM sodium periodate. This treatment did
not affect the staining after incubation of the rNB2 VLPs (data not
shown). Tissue sections were thus pretreated with 10 mM
Author Summary
Noroviruses are a major cause of gastroenteritis in humans
and other mammals such as pigs and cows. Various human
strains are known to bind complex sugar structures related
to ABO blood groups. A single strain does not recognize all
people owing to the individual variation in ABO-related
antigens. Binding to these molecules is required for
infection since individuals lacking the appropriate sugar
structures are not infected by a given strain. We now
report that a cow-specific strain binds very specifically to
the so-called xenoantigen, a sugar motif resembling B
blood group antigen, present at the surface of the small
intestine of cows. This antigen is absent from all human
tissues since the human gene encoding an enzyme
required for its synthesis has been inactivated by
mutations during evolution of the Hominidaea lineage.
Although present in other mammals such as pigs, we
observed that this sugar motif is not expressed at the right
location to allow infection, that is, the surface of the small
intestine. Thus, the cow virus should not infect humans or
pigs. Its adaptation to cows would prevent transmission to
other species living in close contact with cows such as man
and pig.
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(Fig. 1E and 1F), suggesting that rNB2 VLPs recognize a neutral
glycan structure expressed both on digestive surface epithelial cells
and other cell types including vascular endothelial cells.
Since other norovirus strains are known to bind to neutral
carbohydrates of the histo-blood group family, we next sought to
determine the expression of such epitopes throughout the bovine
gut in order to relate it to the binding of rNV VLPs. To this aim, a
set of antibodies as well as the UEA-I and GS1-B4 lectins were
used and we observed that some, but not all, of these reagents
clearly labeled bovine gut tissue sections. The A histo-blood group
antigen was detected, but not the B antigen. Strong positivity was
Figure 1. Analysis of rNB2 VLPs binding and of their ligand expression by immunohistology. VLPs at 1 mg/ml were incubated on tissue
sections and detected as described in the Materials and Methods section. Binding of rNB2 VLPs to bovine duodenum surface epithelium (A), glands
(B), smooth muscle (C) and negative control in absence of rNB2 VLPs (D). Effect of a 10 mM sodium periodate treatment prior to VLPs incubation (E)
and serial control section pretreated in the same conditions without periodate (F). Staining of the surface epithelium (G) and vascular endothelium in
connective tissue (H) of bovine duodenum by an anti-aGal mAb. Lack of binding of rNB2 VLPs on human duodenum (I). Binding of rNB2 VLPs to
porcine duodenum (J). Effect of a–galactosidase treatment prior to rNB2 VLPs incubation on a porcine duodenum tissue section (K) and control
section pretreated in the same conditions in absence of enzyme (L). Epithelial cells are indicated by arrows, vascular endothelium cells by small
arrowheads, and smooth muscle cells by a star.
doi:10.1371/journal.ppat.1000504.g001
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contrast, very little or no staining was detected using reagents
specific for type 1 or type 3 based structures. Only the anti-Le
a
antibodies stained scattered goblet cells in the duodenum and
colon, whereas the anti-H type 1, anti-H type 3 and anti-Le
b did
not give detectable specific labeling. Similar to that observed for
rNB2 VLPs ligands, the A and H type 2/LeY expression was most
intense in the pyloric and duodenal surface epithelia and gradually
decreased from distal duodenum to disappear from the distal part
of the digestive tract (Fig. 2). Yet, the expression of these
fucosylated structures was observed on epithelial cells only and
therefore did not match with that of the VLPs. In addition to A
and H histo-blood group epitopes, the aGal epitope detected by
either a mAb or the GS1-B4 lectin was detected in the bovine gut.
The staining obtained with these reagents matched that of the
VLPs since, as with the anti-A and H type 2/LeY, it was maximal
in the gastro-duodenal area and absent from the distal part of the
gut (Fig. 2), but more specifically, since the labeled cells and the
relative intensities of labeling were the same as those observed
following incubation with rNB2 VLPs as described above (Fig. 1G
and 1H). The pattern of labeling obtained with the anti-aGal
reagents was thus indistinguishable from that obtained with the
VLPs, suggesting that the latter might recognize a carbohydrate
structure related to the aGal epitope.
Characterization of the Newbury2 recombinant VLPs
ligand
HBGAs were first characterized on human erythrocytes and it
has been previously shown that hemagglutination (HA) can be
used to define the HBGA specificity of human noroviruses [30].
We thus tested the ability of rNB2 VLPs to agglutinate bovine or
human red blood cells. A strong agglutination of bovine
erythrocytes was obtained both at 4uC and room temperature,
but no agglutination at all was detected using human erythrocytes
at either temperature, irrespective of their ABO phenotypes. In
contrast, a GII.4 strain agglutinated human O blood group red
blood cells, but not bovine erythrocytes (Fig. 3A). Since HBGAs
are also present in saliva, we next assayed the binding of rNB2
VLPs to bovine and human saliva samples. When human saliva
samples were assayed, no signal above background was obtained.
In contrast, using the same amount of VLPs from a GII.4 strain,
all human saliva samples from secretor individuals were strongly
recognized, irrespective of their ABO phenotype. As previously
observed for other human GII.4 strains, saliva samples from
Figure 2. Expression of rNB2 VLPs ligands and of HBGAs along the bovine digestive tract. Expression of rNB2 VLPs epithelial ligands and
HBGAs on the various parts of the digestive tract was determined by immunohistochemistry (see Fig. 1). Intensity of labeling shown on the y axis was
visually graded from strongly positive (grade 3), moderately positive (grade 2) to weakly positive (grade 1) and negative (grade 0). (A) NB2 VLPs
ligands ; (B) aGal epitope detected using either the GS1-B4 isolectin or the 4F102c2 mAb ; (C) A blood group antigen detected using mAb 9113D10
which recognizes all types of A epitopes ; (D) Htype2/Le
y epitopes detected using either the UEA-I lectin, or the 19-0LE mAb. *In addition to epithelial
cells, rNB2 VLPs, GS1-B4 and the 4F102c2 mAb stained the vascular endothelium throughout the digestive tract.
doi:10.1371/journal.ppat.1000504.g002
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the binding (Fig. 3B). On bovine saliva samples, rNB2 VLPs
binding was readily detected, albeit with highly variable OD
values, some samples giving a strong signal and others a signal at
background level only (Fig. 3C). Nearly identical results were
obtained with human natural anti-aGal antibodies (Fig. 3E). The
binding of the UEA-I lectin and of anti-A and anti-B mAbs were
assessed on the same set of samples. No binding of the anti-B was
detected (data not shown). As depicted on Fig. 3D and 3F, the
binding of the UEA-I lectin and of the anti-A mAb were
heterogeneous too, but they were not related to each other, nor to
that of the rNB2 VLPs. This indicates that individual bovine saliva
samples are polymorphic with regard to the presence of either the
A or H antigens. In addition, the lack of concordance between
either the A or H antigens expression and the binding of rNB2
VLPs or human natural antibodies shows that individual
differences in rNB2 VLPs binding were not due to non specific
heterogeneity of the total amount of salivary glycans but were due
to a true heterogeneity of the expression of the capsids ligand and
of the aGal epitope. Taken together, these results clearly indicate
that the ligand recognized by rNB2 VLPs is distinct from A, B or
H antigens, but not from the aGal epitope and that it is not
present on human red blood cells or in human saliva.
In order to define the carbohydrate specificity of rNB2 VLPs,
their ability to recognize a set of HBGAs related oligosaccharides
was determined using an ELISA-based binding assay. The
structure of all the oligosaccharides tested is given in Table 1.
Binding was observed on two structures which share a common
terminal galactose in a1,3 linkage, contrasting with the binding
pattern of the human NV strain (Fig. 4A). None of the other tested
oligosaccharides allowed binding above background. One of the
aGal-terminated structures recognized by the bovine VLPs is
fucosylated on the N-acetylglucosamine residue, generating a
Lewis X epitope (aGal-Le x). The presence of this fucose residue
Figure 3. Red blood cell agglutination and saliva recognition. (A) Agglutination of bovine and human erythrocytes by VLPs from the bovine
NB2 strain (gray bars) and from a human GII.4 strain of the Grimsby type which binds to Le
y (black bars). Erythrocytes from 2 individual cows and
human erythrocytes from A, B or O blood group individuals were used. Results are shown as hemagglutination titers (HA titers). (B) Recognition of
human saliva by VLPs from the bovine NB2 strain and the human Dijon (GII.4) strain determined by ELISA. Saliva samples were grouped into
nonsecretors (white bars), A secretors (black bars), B secretors (dark gray bars) and O secretors (light gray bars) with 4 samples in each group. (C)
Binding of rNB2 VLPs to individual bovine saliva samples determined by ELISA. Individual samples are numbered from 1 to 17 and ranked according
to increasing OD 450 nm values. (D) Expression of the A blood group antigen in individual bovine saliva samples. (E) Expression of the aGal epitope
detected by human natural anti-aGal antibodies in individual bovine saliva. (F) Expression of H/Le
y epitopes detected by the UEA-I lectin in individual
bovine saliva samples. In D, E and F, samples are ranked as in C.
doi:10.1371/journal.ppat.1000504.g003
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preferred structure recognized by rNB2 VLPs among those tested
is the trisaccharide Gala3Galb4GlcNAc. Noticeably, the B blood
group antigen which also presents a terminal galactose in a1,3
linkage was not recognized, consistent with the lack of agglutina-
tion of human B blood group erythrocytes and with the lack of
binding to human saliva samples from B secretors.
In order to determine if the ligand recognized in bovine saliva
and digestive tissues corresponds to the aGal antigen, the effect of
a–galactosidase treatment was tested. A saliva sample that allows
good binding of rNB2 VLPs was chosen (sample # 8). The
binding of VLPs was completely lost following the enzyme
treatment. Activity of the enzyme was controlled using the
Gala3Galb4GlcNAc conjugate and binding to the treated
conjugate was similarly lost after a–galactosidase treatment
(Fig. 5A). The same treatment was applied to a bovine duodenal
tissue section and staining completely disappeared (data not
Figure 4. Binding of rNB2 VLPs to immobilized synthetic
oligosaccharides. (A) A panel of neoglycoconjugates was coated on
ELISA plates at 10 mg/ml and binding of either NB2 (white bars) or NV
VLPs (black bars) was detected as described in the Materials and
Methods section. OD 450 nm values on selected glycoconjugates are
shown. No positive values were recorded for any of the other
glycoconjugates listed in Table 1. (B) Binding of rNB2 VLPs to serially
diluted structurally related PAA-conjugates. White squares: aGal
trisaccharide ; black triangles: aGal-Lex ; black squares: mean of other
PAA-conjugates (see Table 1 for structures). Results are shown as OD
450 nm as a function of the reciprocal of PAA-conjugate dilutions with
1/25 corresponding to 40 mg/ml.
doi:10.1371/journal.ppat.1000504.g004
Table 1. Neoglycoconjugates used to determine the
carbohydrate specificity of rNB2 VLPs.
Trivial name Oligosaccharide structure
a
Tn GalNAca-R1
a–galactose monosaccharide Gala-R1
a–fucose monosaccharide Fuca-R1
A disaccharide GalNAca3Galb-R1
B disaccharide Gala3Galb-R1
Gala2Galb-R1
Gala6Glcb-R1
Core 5 GalNAca3GalNAca-R1
H disaccharide Fuca2Galb-R1
Forsmann disaccharide GalNAca3GalNAcb-R1
Core 8 Gala3GalNAca-R1
Type 2 precursor Galb4GlcNAcb-R1
Tab Gala3GalNAcb-R1
A trisaccharide GalNAca3(Fuca2)Galb-R1, R2
B trisaccharide Gala3(Fuca2)Galb-R1, R2
H type 1 Fuca2Galb3GlcNAcb-R1
H type 2 Fuca2Galb4GlcNAcb-R1, R2
H type 3 Fuca2Galb3GalNAca-R1
aGal trisaccharide Gala3Galb4GlcNAcb-R1
Gb3 (Pk) Gala4Galb4Glcb-R1
iGb3 Gala3Galb4Glcb-R1
P1 trisaccharide Gala4Galb4GlcNAcb-R1
Lewis a Galb3(Fuca4)GlcNAcb-R1
Lewis x Galb4(Fuca3)GlcNAcb-R1
39-Sulfo-Lewis a Su-O-3Galb3(Fuca4)GlcNAcb-R1
39-Sulfo-Lewis x Su-O-3Galb4(Fuca3)GlcNAcb-R1
A type 2 GalNAca3(Fuca2)Galb4GlcNAcb-R1
B type 2 Gala3(Fuca2)Galb4GlcNAcb-R1
Lewis b Fuca2Galb3(Fuca4)GlcNAcb-R1, R3
Lewis y Fuca2Galb4(Fuca3)GlcNAcb-R1, R2
Sialyl-Lewis a NeuAca2,3Galb3(Fuca4)GlcNAcb-R1, R3
Sialyl-Lewis x NeuAca2,3Galb3(Fuca4)GlcNAcb-R1, R3
6-sulfo Sialyl-Lewis x NeuAca2,3Galb3(Fuca4)(Su-O-6)GlcNAcb-R1
Tk GlcNAcb3(GlcNAcb6)GlcNAcb3Galb-R1
Lacto-N-tetraose (LNT) Galb3GlcNAcb3Galb4Glcb-R3
Lacto-N-neotetraose (LNnT) Galb4GlcNAcb3Galb4Glcb-R3
a-Gal-Lewis x Gala3Galb4(Fuca3)GlcNAcb-R1
a-Gal pentasaccharide Gala3Galb4GlcNAcbGalb4Glcb-R1
Sialyl-Lewis x pentasaccharide NeuAca2,3Galb3(Fuca4)GlcNAcb3Galb-R1
Sialyl-lacto-N-neotetraose
(Sia-LNnT)
NeuAca2,3Galb4GlcNAcb3Galb4Glcb-R1
Lactoneofucopentaose I (LNF I) Fuca2Galb3GlcNAcb3Galb4Glcb-R1, R3
Lacto-N-fucopentaose II
(LNF II)
Galb3(Fuca4)GlcNAcb3Galb4Glcb-R3
Lacto-N-fucopentaose III
(LNF III)
Galb4(Fuca3)GlcNAcb3Galb4Glcb-R3
A hexasaccharide GalNAca3(Fuca2)Galb3GlcNAcb3Galb4Glcb-R3
A heptasaccharide GalNAca3(Fuca2)Galb3(Fuca4)GlcNAcb3Gal-
b4Glcb-R3
aOligosaccharides were used coupled to either polyacrylamide via an 3 carbon
spacer (R1), or to human serum albumin via either a p-aminophenylethyl
spacer (R2) or an acetyl phenylenediamine spacer (R3).
doi:10.1371/journal.ppat.1000504.t001
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anti-aGal antibodies could inhibit the binding of rNB2 VLPs to
bovine saliva samples (Fig. 5B). These results indicate that rNB2
VLPs specifically recognize the aGal antigen of the HBGAs family
in bovine saliva and digestive tract.
The binding epitope of Gala3GalbOMe at atomic
resolution
Binding of the Galili disaccharide (Gala3GalaOMe) to rNB2
VLPs was studied using saturation transfer difference (STD) NMR
experiments [31]. This technique allows identification and
characterization of ligand binding to large receptor proteins and
yields binding epitopes of the ligand molecules at atomic
resolution. It has been shown lately that the technique is well
suitable for the investigation of carbohydrate receptor recognition
by caliciviruses [32]. STD NMR spectra of Gala3GalaOMe and
of the methyl glycoside of the blood group B trisaccharide in the
presence of rNB2 VLPs at a saturation time of 2 s are shown in
Fig. 6. The Galili disaccharide yielded sizable STD effects whereas
no response at all was observed for the B-trisaccharide. This is in
accordance with the biological assays that could not detect any
binding to the B-antigen and underlines the strict specificity of the
VLPs for the disaccharide moiety Gala3GalaOMe. STD NMR
experiments of Gala3GalaOMe in the presence of rNB2 VLPs
with increasing saturation times yielded STD build-up curves for
individual protons. Fitting of these data to a single-exponential
function (cf. Materials and Methods) delivered the binding epitope.
It has been shown that strong spin-diffusion within large virus like
particles requires the acquisition of build-up curves instead of
single point measurements in order to generate reproducible
binding epitopes. The binding epitope of Gala3GalaOMe derived
from this analysis is shown in Fig. 7. It is remarkable that the
protons around the glycosidic linkage received the largest fraction
of saturation. This suggests that the a3-glycosidic linkage is in
intimate contact with the VLP binding pocket. Obviously, the
Galili disaccharide represents the central recognition element.
Species specificity of the rNB2 VLPs ligand
The aGal is not expressed in apes due to inactivation of the
GGTA1 gene encoding the a1,3galactosyltransferase. Yet, it has
been detected in all other mammalian species tested so far [17].
The lack of agglutination of human red blood cells and of binding
to human saliva by rNB2 VLPs is consistent with the inability of
humans to synthesize this antigen. In addition, no binding to the
Figure 5. Inhibition of binding to bovine saliva by a-galactosidase treatment or by human natural anti-aGal antibodies. (A) Bovine
saliva from a positive individual (#8) or PAA-conjugates (aGal trisaccharide and aGalNAc, see Table 1 for structures) were coated at a 1/1000 dilution
or 10 mg/ml respectively and either treated with a–galactosidase from green coffee beans (white bars) or enzyme buffer only (black bars). (B) Bovine
saliva from 2 positive individuals (#8 and #12) were coated as above and incubated with purified human anti-aGal (white bars) or blocking buffer
only (black bars) for 2 hours prior to addition of rNB2 VLPs. Binding of VLPs was detected as described in the Materials and Methods section and
shown as OD 450 nm values. Dashed lines indicate background level.
doi:10.1371/journal.ppat.1000504.g005
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VLPs do not cross react with a human epitope present in the
human gut (Fig. 1I).
Since pigs are known to be infected by noroviruses, and since
they are known to express the aGal antigen, we tested the binding
of rNB2 VLPs to the porcine gut by immunohistochemistry. A
specific staining was readily observed throughout the digestive
tract but surprisingly, it was restricted to non epithelial cells,
including the vascular endothelium and to a lesser extent smooth
muscle cells (Fig. 1J). Porcine duodenal tissue sections were then
treated with the a–galactosidase from green coffee beans. Like on
bovine tissue sections, the treatment completely abolished the
binding of rNB2 VLPs to these cell types (Fig. 1K and 1L). The
distribution of the aGal antigen in porcine digestive tract was then
tested using an anti-aGal mAb and the GS1-B4 lectin. We
observed that the two reagents gave stainings completely parallel
with that obtained with the rNB2 VLPs (data not shown). This
indicates that in porcine tissues, the aGal epitope is not expressed
by digestive epithelial cells although it is present on other cells
types recognized by the bovine viral capsids.
Since the lack of aGal antigen in humans is due to inactivation
of the GGTA1 gene, we tested whether this event was sufficient to
have caused the lack of recognition of human cells by rNB2 VLPs.
Transfection of human HEK 293 cells with the functional rat
Ggta1 cDNA allowed expression of the aGal antigen as detected by
flow cytometry using the GS1-B4 lectin. Control HEK 293 cells
that lacked the aGal antigen were barely recognized by rNB2
VLPs. In contrast, a clear binding was observed on the Ggta1
transfected human cells. Inversely, pig vascular endothelial cells
spontaneously express the aGal antigen as documented from the
labeling by the GS1-B4 lectin. The attachment of rNB2 VLPs to
such cells was clearly detected by flow cytometry. However, we
Figure 6. Observation of STD signals for the aGal disaccharide and the blood-group B trisaccharide. (A) Reference
1H NMR spectrum
and (B) STD NMR spectrum of Gala3GalaOMe in the presence of bovine norovirus VLPs. (C) Reference
1H NMR spectrum and (D) STD NMR spectrum
of the methyl glycoside of the blood group B-trisaccharide in the presence of bovine norovirus VLPs. STD signals are only observed for
Gala3GalaOMe. The blood group B-trisaccharide shows no STD effects, and is therefore not recognized by the VLPs. Spectra were recorded at
500 MHz at a temperature of 282 K with 256 and 816 scans, respectively.
doi:10.1371/journal.ppat.1000504.g006
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which accordingly are not stained by GS1-B4, were no longer
recognized by the bovine VLPs (Fig. 8). These results confirm that
rNB2 VLPs bind to the aGal antigen and that the expression of a
functional a1,3galactosyltransferase is necessary and sufficient to
allow their attachment to mammalian cells.
Discussion
RNA viruses present a high risk of cross-species transmission
since they are over-represented in the list of pathogens known to
have crossed the species barrier [33]. This is most likely due to
their particularly high mutation rate which allows them to evolve
fast, providing rapid adaptation to a new host species. The use of
phylogenetically conserved ligands facilitates the crossing of the
species barrier. Since among Caliciviruses, human strains of
norovirus and the rabbit hemorrhagic disease virus bind to
HBGAs and since HBGAs can be phylogenetically conserved, we
tested the possibility that the prototype of the bovine NoV, the
Newbury2 strain classified in the GIII.2 cluster, could use such a
conserved carbohydrate ligand to bind to bovine, porcine or
human digestive epithelial cells. Our results demonstrated that
VLPs from NB2 attach to the surface of the bovine duodenal
epithelium by recognition of the aGal epitope of the HBGAs
family and that this ligand cannot be used to infect either man or
pig. This conclusion is based on the following observations: (1) the
tissue distribution of rNB2 VLPs binding sites in the three species
perfectly matched that of reagents specific for the aGal epitope
which is absent from human and pig duodenal epithelial cells ; (2)
among many immobilized HBGAs-related synthetic oligosaccha-
rides, only those presenting the aGal epitope supported binding of
the VLPs ; (3) a-galactosidase treatment of either tissue sections or
bovine saliva completely impaired the binding of rNB2 VLPs ; (4)
STD NMR experiments confirmed recognition of the aGal
epitope at the atomic level ; (5) transfection of human cells with an
a1,3galactosyltransferase cDNA allowed binding of rNB2 VLPs
whilst inversely, their binding to porcine vascular endothelial cells
was lost on cells from an a1,3galactosyltransferase KO pig.
The aGal epitope is structurally related to the histo-blood group
antigen B type 2 since both share a terminal galactose in a1,3
linkage and the type 2 backbone structure (Galb4GlcNAc). They
only differ by the fucose residue of the B antigen, allowing some
reagents such as some anti-B mAbs or the GS1-B4 isolectin to
cross-react. Nevertheless, the possibility that rNB2 VLPs could
recognize a B blood group epitope in addition to the aGal antigen
is very unlikely since it failed to agglutinate human B blood group
erythrocytes and to bind to human saliva from B blood group
individuals of the secretor phenotype who strongly express B
Figure 7. Binding epitope of Gala3GalaOMe binding to rNB2 VLPs (top) as derived from STD build-up curves (bottom). Greyscale
circles encode the relative size of the saturation transfer and reflect the vicinity to protons in the binding pocket of rNB2 VLP. The larger the
saturation transfer, the closer are the ligand protons to protons of the VLP binding pocket. From the Figure it is seen that the region around the
glycosidic linkage is essential for recognition by the VLPs.
doi:10.1371/journal.ppat.1000504.g007
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by STD NMR experiments that the a3-glycosidic linkage serves as
the central recognition element. Any disturbances close to this
region such as the addition of a fucose residue in the 2-position of
the reducing galactose moiety to yield the B-antigen would
therefore impede with the binding process. One may speculate
whether other positions that are more remote from the glycosidic
linkage may be modified so as to obtain a better binder.
Interestingly, we did not detect B blood group reactivity on cow
tissue sections or saliva, making less likely the possibility for GIII.2
strains to evolve toward cross-recognition of the aGal and the B
epitopes. Besides the species-specific expression of the aGal
antigen on bovine digestive epithelial cells, another species-specific
bovine characteristic was evidenced with regard to HBGAs
expression. Indeed, we failed to detect HBGAs based on type 1
precursor (Galb3GlcNAc) in bovine tissues or saliva, consistent
with the results from earlier structural analyses of O-linked
oligosaccharides from bovine salivary mucins which described the
presence of type 2-based structures only [34,35]. Those studies
also failed to detect the aGal epitope. However, it could either be
carried by N-linked glycans of salivary glycoproteins or the saliva
studied could have originated from animals that did not express
the epitope, consistent with our observation that not all bovine
saliva samples could support attachment of rNB2 VLPs. Human
NoV of either the GI or GII genogroups recognize HBGAs motifs
based on both type 1 and type 2 precursors, but show stronger
binding to type 1-based structures, particularly at 37uC [36,37].
Human small intestine presents HBGAs based on type 1 as well as
on type 2 backbones, suggesting adaptation of these strains to their
host glycans. Even though cows can express A and H type 2 or Le
y
antigens in their digestive tract, they may be less sensitive to
infection by human NoV strains due to the lack of type 1-based
structures. Interestingly, using saliva samples, we observed that
similar to man and pig, cows are polymorphic regarding
expression of the A and H antigens since some cows did not
express either A, H or both. As these polymorphisms were
unrelated to the aGal expression, the combination of the A, the H
and the aGal polymorphisms is expected to generate eight
subgroups of bovine and therefore significant individual variation
which may be related to host-pathogens interactions.
Regardless, our results do not prove that the aGal ligand is
necessary for infection of cows by GIII.2 strains, but several
aspects support that possibility. Various human NoV strains that
bind to HBGAs have been shown to infect their host in an HBGA-
dependent manner [15]. Likewise, we recently obtained indirect
evidence that the binding of RHDV, a lagovirus, to the H type 2
antigen is necessary for infection [38]. Thus, the conservation of
the binding ability of an HBGA motif by the Newbury2 strain
suggests that it may also be required for infection. Furthermore,
histopathological analysis of the lesions of calves experimentally
infected with NB2 indicated that they were restricted to the
proximal small intestine [11], which coincides with the main site of
expression of the aGal antigen on digestive epithelial cells. Finally,
there is no clear evidence that bovine NoV can infect an other
species [8]. Such viruses have never been detected in human or
porcine samples, suggesting that they do not circulate in those
Figure 8. Cytofluorimetric analysis of the binding of rNB2 VLPs and the GS1-B4 lectin to rat Ggta1 transfected or control mock
transfected HEK 293 cells and to porcine aortic endothelial vascular cells (PAEC) from wild type or Ggta1 KO pigs. Cells were
incubated with either the GS1-B4 lectin or rNB2 VLPs and binding was detected as described in the materials and methods section. The respective
negative controls (grey plots) correspond to either cells incubated in absence of the lectin or to cells incubated in the absence of VLPs. Another
negative control performed in the presence of VLPs followed by incubation with an irrelevant immune rabbit antiserum and FITC-labeled anti-rabbit
IgG yielded similar results. The log of fluorescence intensities in arbitrary units is plotted against the cell number.
doi:10.1371/journal.ppat.1000504.g008
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receptor for infection. Nonetheless, one study described the
presence of anti-GIII.2 antibodies in the serum of veterinarians
in the Netherlands [23]. Bovine NoVs share cross-reactive
epitopes with human NoVs [39,40]. This cross-reactivity may
explain the detection of anti-GIII.2 in some human serum
samples.
In absence of cell culture models, it is very difficult to prove that
a ligand is truly a receptor. The above described demonstrations
that HBGAs can be compulsory ligands have been obtained
through the analysis of the effect of their polymorphism on
infection [41,42,43,44]. Interestingly, we observed that the rNB2
VLPs salivary binding assay could distinguish between binder and
non binder cows. If that polymorphism is also present at the level
of digestive epithelial cells, it could be used to experimentally assay
the sensitivity of either group to infection by the Newbury2 strain.
To date recombinants of bovine NoV and HuNoV have been
identified and appear to be of frequent occurrence
[4,45,46,47,48]. Cattle co-infection by a GIII.2 bovine strain
and a human NoV could thus lead to the emergence of
recombinant strains able to infect humans. However, this seems
unlikely since as discussed above, the lack of type 1-based HBGAs
in cow digestive epithelium may decrease recognition by HuNoVs,
and since GI, GII and GIII strains are genetically distant and
accordingly, inter-genogroup recombination, although recently
observed, should be much less frequent than intra-genogroup
recombination [4,49].
Recent crystallographic analyses of the capsid protein domain of
a GI.1 and a GII.4 NoV interacting with oligosaccharides showed
that the two strains use distinct binding sites on the capsid protein
protruding domain, although they bind to very similar oligosac-
charides [50,51]. A fucose residue is involved in both instances,
although it is more essential to the GII.4 binding site than to the
GI.1 binding site. Here we showed that the best binder of a GIII.2
strain is a related carbohydrate structure devoid of fucose and that
addition of an a1,3-linked fucose to the backbone N-acetylgluco-
samine impaired recognition. It will thus be interesting to define
the mode of recognition of the aGal trisaccharide by the NB2
strain in order to know if its binding site corresponds to one of
those already characterized for either GI or GII strains. This
knowledge should provide crucial information to understand how
NoVs adapt to their host species and evolve to maintain
recognition of diverse HBGAs that allow binding to allotypic
and/or xenotypic host molecules.
The Galili antigen has mainly been studied in the context of
xenotransplantation since it was originally observed that humans
naturally produce antibodies against it and since these antibodies
were shown to be the primary cause of hyperacute rejection of pig
xenografts organs in human and hominids [17]. But the reason
why the GGTA1 gene has been inactivated in the Hominidaea
lineage an estimated ,28 MA ago is unclear. The loss of the aGal
epitope allows the generation of so-called natural antibodies,
similar to the generation of anti-A or anti-B natural antibodies in
the ABO allogenic system, probably because some bacteria express
identical or cross-reactive epitopes. These anti-aGal antibodies
can recognize pathogens that carry the xenogenic epitope. Thus,
envelopped viruses produced in animal cells that express a
functional a1,3galactosyltransferase carry the aGal antigen on
their envelope glycoproteins and the presence of natural antibodies
directed against this epitope in human serum leads to their rapid
elimination [52,53]. For this reason it has been proposed that
inactivation of the GGTA1 gene in the Hominidaea lineage may
have allowed escape from a highly pathogenic virus thanks to the
natural anti-carbohydrate antibodies [17]. Our observation that
an animal pathogen can use the aGal antigen as a ligand
additionally suggests that the loss of GGTA1 may have allowed
escape from some NoV strains. Clearly, at present GIII NoVs are
of moderate or low pathogenicity. Nevertheless virulence evolves
and past NoVs may have been much more virulent than present
ones. The loss of the aGal ligand may have contributed to escape
dreadful past NoV epidemics in hominids. Alternatively, the loss of
the GGTA1 enzyme may have been completely independent from
NoV infection. In this case, NoVs would have more recently
evolved carbohydrate-binding specificities adapted to a broad
spectrum of mammalian species. Regardless, the exquisite
specificity of the NB2 strain for the aGal epitope is well adapted
to its bovine host, but inversely should restrict its possibilities of
cross-species transmission.
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies.
Reagents
The BG-4 anti-H type 1 specific monoclonal antibody (mAb)
was purchased from Signet laboratories (Dedham, CA) and mAbs
19-OLE, 7-LE and 2-25LE were obtained from Dr. J. Bara
(CNRS, Villejuif, France). They are an anti-H type 2 showing a
slight cross-reactivity with Le
y (unpublished results), an anti-Le
a
and an anti-Le
b, respectively. The anti-H types 3 and 4 mAb
MBr1 was purchased from Covalab (Villeurbanne, France). The
anti-A (all types) mAb 9113D10 was obtained from Diagast (Loos,
France). The anti-B mAb ED3 was a kind gift from Dr. A. Martin
(CRTS, Rennes, France). The anti-aGal 4F102c2 was a kind gift
from Dr. A. Bendelac (Howard Hughes Medical Institute,
Chicago, IL). The lectin from Griffonia simplicifolia B4 isolectin 1
(GS1-B4), either peroxidase or fluorescein isothiocyanate (FITC)
conjugated, which recognizes a1,3-linked terminal galactosyl
residues, was purchased from EY Laboratories (San Mateo, CA
USA) and Vector Laboratories (Burlingame, CA USA), respec-
tively. The lectin from Ulex europaeus (UEA-1) peroxidase
conjugated, which recognizes H type 2 and Le
y was obtained
from Sigma (St Louis, MO). Alpha-galactosidase from green coffee
beans was purchased from Sigma. The anti-GII and anti-GIII
rabbit polyclonal antisera were prepared at the Veterinary School
of Nantes by immunizing rabbits with VLPs from GII.4 (Dijon
171/96) and GIII.2 (NB2) strains, respectively.
Synthetic oligosaccharides as polyacrylamide conjugates were
prepared as described previously [54,55]. Oligosaccharides
coupled to HSA (human serum albumin) were obtained from
IsoSep AB (Tulligen, Sweden). The structure of all oligosaccha-
rides used is given on Table 1. The disaccharide Gala3GalaOMe
was obtained from Calbiochem. The methyl glycoside of the B
antigen has been synthesized enzymatically [56].
Preparation of VLPs
The recombinant virus-like particles were prepared by infecting
High-five insect cells with recombinant baculoviruses according to
a previously described method [57]. The Dijon GII.4 171/96
strain [58] and the GI.1 Norwalk strain (NV) constructs were kind
gifts of Dr. E. Kohli (University of Burgundi, Dijon, France) and
Dr. X. Jiang (Cincinnati Children’s Hospital Medical Center,
Cincinnati, Ohio, USA), respectively. Five days post-infection
High-Five lysed cells and media were centrifuged at 4500 rpm for
15 min and the supernatants collected and centrifuged at 25,
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in distilled water and submitted to 2 rounds of purification on a
sucrose gradient. The gene encoding the capsid protein of the NB2
norovirus cloned into pFastBac vector (InVitrogen) was a kind gift
of Drs S. Oliver and J. Bridger (Royal Veterinary College
London). Competent E. coli DH10BAC cells, containing baculo-
virus shuttle vector plasmid were used to generate recombinant
bacmids according to the manufacturer’s instructions (Invitrogen).
Bacmids were introduced into Spodoptera frugiperda 9 (Sf9) insect
cells by lipofection and recombinant baculovirus were recovered.
NB2 VLPs were produced by infection of Spodoptera frugiperda 9
(Sf9) insect cells at a MOI,5 PFU/cell. VLPs were purified as
described previously [59] by double CsCl density gradient
centrifugation. The composition of the VLPs was confirmed by
polyacrylamide gel electrophoresis with Coomassie blue staining
and VLP integrity was monitored by negative stain electron
microscopy using 1% uranyl acetate stain. VLPs were stored in
CsCl at 4uC.
Tissue samples and immunohistochemical analysis
Bovine and porcine tissues samples from the oesophagus to the
rectum were obtained from healthy animals autopsied at the
National Veterinary School of Nantes. Human gastroduodenal
junction samples had been obtained from organ donors before the
law 88–1138 of December 20, 1988 concerning resection of
human tissues after death for scientific investigations. Animal
tissues were fixed in formalin and human tissues were fixed in
ethanol 95% for 48 hours, and paraffin embedded. Sections
(5 mm) were rehydrated in graded ethanol and washed in
phosphate-buffered saline (PBS). Endogenous peroxidase was
inhibited by using methanol/H2O2 0.3% for 20 minutes. Sections
were then washed in PBS for 5 minutes and covered with PBS/
bovine serum albumin (BSA) 1% for 30 minutes at room
temperature in a humid atmosphere. After washing in PBS,
sections were covered with either the primary antibodies (HBGAs
mAbs), with the peroxidase-conjugated GS1-B4 or UEA-I lectins
at 10 mg/mL, or with rNB2 VLPs at 1 mg/ml, diluted in PBS/
BSA 1% and left at 4uC overnight. Sections were then rinsed 3
times with PBS and incubated with either biotinylated anti-mouse
immunoglobulin IgG (Vector Labs, Burlingame, CA) or with
rabbit anti-NB2. After washing in PBS, the sections were covered
with either peroxidase-conjugated avidin (Vector laboratories) or
with peroxidase conjugated anti-rabbit IgG (Uptima, Montluc ¸on,
France) for 45 minutes. Reactions were revealed with 3-amino-9-
ethylcarbazol, and counterstaining was performed with Mayer’s
hemalun.
Periodate treatment was performed immediately after the
endogenous peroxidase quenching step by incubating sections
with either 1 mM or 10 mM sodium periodate in 50 mM sodium
acetate buffer, pH 5.0, for 30 minutes at room temperature,
followed by a 10 minutes incubation with 1% glycine in PBS.
Control sections were treated similarly with the same buffer but
without sodium periodate. Alpha-galactosidase treatment was
performed on some sections by incubation at 37uC with 4 mU
galactosidase in 50 mM citrate-phosphate buffer pH 4.6 for a total
of 18 hours with a renewal after 6 hours. Control sections were
incubated in parallel in the same buffer without the enzyme.
Following treatments, rNB2 VLPs (1 mg/ml) were added for
1 hour at room temperature and the detection of binding was
performed as described above.
Hemagglutination assay
Bovine blood samples were obtained from the National
Veterinary School of Nantes and human blood samples were
provided by ABO phenotyped volunteer donors at INSERM
U892 (Nantes, France). After collection, whole blood samples were
stored at 4uC. Red Blood Cells (RBC) were packed in PBS pH 7.2
(without Ca
2+) by centrifugation for 5 minutes at 2500 rpm. The
hemagglutination activity (HA) of rNB2 VLPs and GII.4 VLPs
was tested in microtitration plates with V bottomed wells (Nunc,
Roskilde, Denmark). Equal volumes (25 ml) of VLPs (2.5 mg/ml)
serially diluted in PBS and 1% packed RBCs in PBS were mixed
and the plates were incubated for 1 hour at either room
temperature or 4uC. The HA titer was the reciprocal of the
greatest VLPs dilution that did allow sedimentation of the RBCs
compared to negative control wells that contained buffer only.
Purification of human natural anti-aGal antibodies
The synthetic trisaccharide Gala3Galb4GlcNAc covalently
linked to SepharoseH FF (Fast Flow 6B, Pharmacia Biotech) was
obtained from Lectinity (Moscow, Russia). A chromatography
column (Biorad Richmond, CA) was packed with 15 ml of
immunoadsorbent and rinsed with 250 ml PBS. Thirty ml pooled
human plasma were then passed through the column at a 1 ml/h
flow rate. After extensive washing with PBS, bound antibodies
were eluted with 20 ml of CH3COOH 0.58% in NaCl 0.9%,
pH 2.8. The eluate was immediately neutralized with 20 ml of
100 mM Tris/HCl, pH 8.8 and dialyzed against PBS. The
reactivity and specificity of the purified antibodies was then
controlled by ELISA on coated PAA neoglycoconjugates.
ELISA-based carbohydrate and saliva microtiter plate
assays
Oligosaccharides as PAA and HSA conjugates were coated at
10 mg/ml or serially diluted onto NUNC Maxisorp immunoplates
in 100 mM carbonate buffer pH 9.6 by overnight incubation at
37uC in a wet atmosphere. After blocking with 5% defatted dried
cow’s milk in PBS for 1 hour, VLPs (4.6 mg/ml) in PBS 5% milk
were added. After incubation for 2 hours at 4uC in the case of
oligosaccharides-PAA or at 37uC for oligosaccharides-HSA, rabbit
anti rNB2 VLPs serum at 1/1000 dilution in PBS 5% milk was
added and incubated for 1 hour at 4uC. Then, peroxidase anti-
rabbit IgG (Uptima) at a 1/2000 dilution in PBS 5% milk were
added and incubated for 1 hour at 4uC. Between each step, the
plates were washed 3 times with PBS 5% Tween 20. The enzyme
signals were detected using TMB (3, 39,5 ,5 9 tetramethylbenzi-
dine) as substrate (BD Bioscience, San Jose, CA) and then read at
450 nm.
Saliva samples were collected from 16 human individuals of
known ABO and secretor phenotypes [37], and from 16 cows from
the National Veterinary School of Nantes, respectively. After
collection, samples were boiled for 10 minutes and centrifuged for
5 minutes at 13,000 g. To assay rNB2 VLPs binding to saliva,
microplates were coated with either human or bovine saliva
diluted 1/1000 in 100 mM carbonate buffer, pH 9.6 and the assay
was performed as described above using rNB2 VLPs at a 1 mg/ml
concentration and a 1 h incubation at 37uC.
To detect HBGAs in bovine saliva, after coating, a blocking step
was performed with ELISA Synblock reagent (Serotec, Kidlington,
UK) for 2 hour at 37uC. Either peroxidase-conjugated UEA-I
lectin at 2 mg/ml, monoclonal antibodies at a 1/1000 dilution, or
purified human natural anti-aGal antibodies at 50 mg/ml were
then added to the wells. Reagents incubations were performed at
37uC for 1 h. Binding was detected either immediately following
PBS washings for the UEA-I lectin, or following a 1 h incubation
at 37uC with either anti-mouse or human anti-IgG peroxidase
conjugates (Uptima), at a 1/2000 dilution.
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aGal was performed by mixing VLPs at 1 mg/ml with the purified
antibodies at 50 mg/ml for 2 h at 37uC prior to incubation onto
the coated bovine saliva samples. After a 1 h incubation at 37uC,
binding of the rNB2-VLPs was detected as above.
NMR experiments
NMR samples contained 0.24 mg/ml or 22.5 nM VLPs in
23 mM phosphate buffer pH 7, 154 mM sodium chloride.
Assuming a number of 180 monomers and 90 binding sites per
capsid, this corresponds to a 4.06 mM concentration of monomers,
and to a 2.03 mM concentration of binding sites. Samples
contained 0.5 mM carbohydrate ligand, resulting in a ,1:250
molar ratio of binding sites to ligand. All experiments were carried
out on a Bruker Avance 500 MHz NMR spectrometer equipped
with a TCI cryogenic probe. The temperature was set to 282 K.
STD NMR experiments [31] were recorded with a 3-9-19
watergate sequence and an inter-scan delay of 25 s [60]. On-
and off- resonance frequencies were set at 24 and 300 ppm,
respectively [32]. A train of Gaussian pulses with a pulse length of
49 ms, an inter-pulse delay of 1 ms, and an attenuation level of
50 dB was applied for selective saturation of the protein. Spectra
of Gala3GalaOMe were recorded with increasing saturation times
from 0.35 to 4 s, and a total of 64 to 1k scans. The resulting STD
build-up curves were subjected to non-linear fitting to a mono
exponential equation: STD~STDmax 1{e {ksat t ðÞ 
with STD
being the STD signal intensity at saturation time t, STDmax being
the maximal STD intensity at infinite saturation times, and ksat
being the observed saturation rate constant [61]. The curve fitting
was done with Origin (Microcal) and yielded the relative binding
epitope [62]. STD spectra of the B antigen were recorded at only
one saturation time of 2 s with 816 scans.
Cell culture and transfection
The complete coding sequence of the Ggta1 gene encoding the
rat a1,3galactosyltransferase was cloned as previously described
[21] and inserted into the PCR3.1 eukaryotic expression vector
(InVitrogen, Paisley, UK). Human Embryonic Kidney (HEK) 293
cells, maintained in D-MEM/F-12 supplemented with 10% (v/v)
fetal calf serum (FCS) 2 mM L-glutamine, free nucleotides (10 mg/
mL), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco,
Paisley, UK) were transfected with the rat Ggta1 using
lipofectAMIN
TM (InVitrogen) according to the manufacturer’s
instructions. Stable transfectants were obtained by selection with
0.5 mg/ml G418 (Gibco). Cells were then cultured in the presence
of 0.1 mg/ml G418, passaged at confluence after dispersal with
0.025% trypsin in 0.02% EDTA and routinely checked for
mycoplasma contamination by Hoechst 33258 (Sigma) labeling.
Porcine aortic endothelial cells (PAEC) from a wild type pig,
and from a Ggta1 knockout pig, were obtained from Dr. B.
Charreau (INSERM U643, ITERT, Nantes, France). The cells
were cultured in RPMI supplemented with 10% (v/v) FCS, 2 mM
L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin
(Gibco) at 37uC in a 5% CO2 humid atmosphere. They were
passaged at near confluence as described above.
Flow cytometry analysis
Cells at near confluence were detached by a brief 0.025%
trypsin/0.02% EDTA treatment. Viable cells, 2610
5 per well of
96 culture microtiter plates were incubated with either FITC-
labelled GS1-B4 lectin at 10 mg/ml in PBS 0.1% gelatin or with
rNB2 VLPs at 4.6 mg/ml in PBS 1% BSA for 45 min at 4uC. In
the former case fluorescence analysis was performed immediately
following 3 washes. In the latter case, after 3 washes, incubation
was performed with the rabbit anti-NB2 serum at a 1/1000
dilution for 30 min. Following 3 washings, a 30 min incubation
was then performed with FITC-labeled anti-rabbit IgG (Sigma)
diluted 1/500. Finally after 3 more washings, fluorescence analysis
was performed on a FACSCalibur (Becton Dickinson, Heidelberg,
Germany) using the CELLQUEST program.
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